CPI-613, KGDH and PDH inhibitor; Anticancer activity (TBI3519)

Description

Product Details

Formal Name: 6,8-bis(benzylthio-octanoic acid)

Alternate Names: Devimistat

Molecular Formula: C₂₂H₂₈O₂S₂

Formula Weight: 388.59

CAS Number: 95809-78-2

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 30 mg/ml) or in Ethanol (up to 20 mg/ml)

Storage: -20°C

Stability: ≥ 2 years.

 

Applications

KGDH and PDH inhibitor; Anticancer activity

 

Functions

Lipoic acid analog which potently disrupts mitochondrial metabolism with selectivity for tumor cells in vitro and shows strong antitumor activity in vivo. Inhibits alpha-ketoglutarate dehydrogenase (KGDH) by a redox mechanisms selectively in tumor cells. Inhibits pyruvate dehydrogenase (PDH) as a mechanistically distinct, non-redox, effect. A novel anticancer agent with a mitochondria-targeted mode of action with non-genotoxic properties.. Has been used (along with PS48) to induce a Warburg-like metabolic state in fibroblasts. Combination treatment of CPI-613 and chloroquine inhibits the progression of clear cell sarcoma in a mouse model.

 

Application Procedures

First dissolved in DMSO (up to 30 mg/ml) or in Ethanol (up to 20 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

Additional information

SIZE (mg)	25 MG, 5 MG

TBI3519_CPI-613